共 102 条
[1]
Elliott PM(2014)2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC) Eur Heart J 35 2733-2779
[2]
Anastasakis A(2020)2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines J Am Coll Cardiol 76 e159-240
[3]
Borger MA(2017)Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy Circ Res 121 749-770
[4]
Ommen SR(2011)2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 58 e212-e260
[5]
Mital S(2016)Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives Eur J Heart Fail 18 1106-1118
[6]
Burke MA(1995)Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary Artery Risk Development in (Young) Adults Circulation 92 785-9
[7]
Marian AJ(2015)New perspectives on the prevalence of hypertrophic cardiomyopathy J Am Coll Cardiol 65 1249-1254
[8]
Braunwald E(2019)Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial Ann Intern Med 170 741-748
[9]
Gersh BJ(2006)Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction Circulation 114 2232-2239
[10]
Maron BJ(2018)Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy J Am Heart Assoc 7 e006657-668